Testing an immune protein to prevent virus reactivation after kidney or liver transplant

This study is testing whether CytoGam®, an immune protein made from donated blood, can help protect kidney and liver transplant recipients from developing a serious viral infection called CMV disease. After transplant, your immune system is intentionally weakened to prevent it from rejecting your new organ, which makes you vulnerable to this virus. The medication is given as three monthly infusions after you finish your standard antiviral prevention treatment.

CMV is one of the most common and serious infections that can happen after organ transplant, especially when a donor had the virus but you didn't before receiving the organ. While doctors give preventive antiviral medications for the first few months after transplant, the virus can still reactivate later and cause life-threatening illness. This trial is testing whether this medication could provide extra protection during that higher-risk period.